Rani Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Corporate Update
22 mars 2023 16h05 HE
|
Rani Therapeutics, LLC
- Anticipates initiating first Phase 2 clinical study in RT-102 in 2H of 2023 - - Announced topline results from the Phase 1 repeat-dose study of RT-102 for the treatment of osteoporosis - -...
Rani Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates
16 mars 2023 16h05 HE
|
Rani Therapeutics, LLC
SAN JOSE, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Entera Bio Announces FDA’s Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis
15 févr. 2023 10h00 HE
|
Entera Bio Ltd.
Type D meeting protocol submission builds on concurrence reached with FDA following successful Type C meeting and supports potential Phase 3 initiation in H2 2023 JERUSALEM, Feb. 15, 2023 (GLOBE...
Entera Bio to Participate in the SVB Securities Global Biopharma Conference
13 févr. 2023 09h00 HE
|
Entera Bio Ltd.
JERUSALEM, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a late-clinical stage, leader in the development of orally delivered peptides and therapeutic...
Bone Health Technologies announces positive Topline Results from Groundbreaking Pivotal Trial of Non-pharmacological Treatment for Osteopenia
05 déc. 2022 15h22 HE
|
Bone Health Technologies
SAN FRANCISCO, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Bone Health Technologies (BHT), a leading innovator of technologies for improving bone health, announces today topline results of its pivotal trial...
Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis
06 oct. 2022 07h00 HE
|
Entera Bio Ltd.
JERUSALEM, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, announced...
Global Eggshell Membrane Market Predicted to Surpass $192.5 Million by 2026 and Grow at 9.6% CAGR Post COVID-19 Pandemic | Affirmed by Research Dive
05 oct. 2022 09h05 HE
|
Research Dive
New York, USA, Oct. 05, 2022 (GLOBE NEWSWIRE) -- According to the report published by Research Dive, the global eggshell membrane market is projected to garner a revenue of $192.5 million by 2026...
Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial
19 sept. 2022 01h15 HE
|
Novartis Pharma AG
ROSALIA study met primary endpoints, confirming proposed biosimilar denosumab matches reference product in terms of pharmacokinetics, pharmacodynamics, efficacy, safety and immunogenicity in...
Orthopedic Fracture Repairing Implants for Osteoporosis Market to Attracts Profitable Prospects due to Rising Number of Road Accidents and Bone-related Disorders, Notes TMR Review
05 août 2022 12h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global orthopedic fracture repairing implants for osteoporosis market is estimated to...
Rich Insights Into The Robust Osteoporosis Clinical Trials Pipeline Analysis By DelveInsight
03 août 2022 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Rich Insights Into The Robust Osteoporosis Clinical Trials Pipeline Analysis By DelveInsight Increasing prevalence and rising geriatric population...